Immediate post-operative PDE5i therapy improves early erectile function outcomes after robot assisted radical prostatectomy (RARP).
Authors
Shukla, Shivani
Sinha, Amil
Sivathasan, Sailantra
Rashid, Amir
Rassam, Joseph
Smart, Sonny
Patel, Keval
Shah, Nimish
Lamb, Benjamin W
Publication Date
2022-02Journal Title
J Robot Surg
ISSN
1863-2483
Publisher
Springer Science and Business Media LLC
Volume
16
Issue
1
Pages
37-43
Language
en
Type
Article
This Version
VoR
Metadata
Show full item recordCitation
Nathan, A., Shukla, S., Sinha, A., Sivathasan, S., Rashid, A., Rassam, J., Smart, S., et al. (2022). Immediate post-operative PDE5i therapy improves early erectile function outcomes after robot assisted radical prostatectomy (RARP).. J Robot Surg, 16 (1), 37-43. https://doi.org/10.1007/s11701-021-01198-4
Abstract
To assess whether the timing of post-operative Phosphodiesterase Inhibitor (PDE5i) therapy after Robot-Assisted Radical Prostatectomy (RARP) is associated with a change in early erectile function (EF) outcomes, continence or safety outcomes. Data were prospectively collected from a single surgeon in one tertiary centre. 158 patients were treated with PDE5i therapy post RARP over a 2-year period. PDE5i therapy was started: immediately (day 1-2) post-op in 29%, early (day 3-14) post-op in 37% and late (after day 14) post-op in 34%. EPIC-26 EF scores were collected pre-op and post-op. There were no significant differences in pre-operative characteristics between the therapy groups. Drop in EF scores and percentage return to baseline for unilateral nerve sparing was, respectively, 9 and 11.1% of immediate therapy, 7 and 14.8% of early therapy and 9.7 and 9.5% of late therapy (p = 0.9 and p = 0.6). For bilateral nerve sparing, this was, respectively, 3.5 and 42.9% immediate therapy, 5.5 and 35.5% early therapy and 7.3 and 25% late therapy (p = 0.017 and p = 0.045). Pad free and social continence were achieved in 54% and 37% of those receiving immediate therapy, 60% and 33% for early therapy and 26% and 54% for late therapy. There were no differences in compliance, complication or readmission outcomes. In patients with bilateral nerve sparing RARP, immediate post-operative PDE5i therapy can protect EF and improve early continence outcomes. Therefore, immediate PDE5i therapy should be considered in patients following nerve sparing RARP to maximise functional outcomes.
Keywords
Original Article, Continence, Erectile dysfunction, Phosphodiesterase inhibitors (PDE5i), Robot-assisted radical prostatectomy (RARP)
Identifiers
s11701-021-01198-4, 1198
External DOI: https://doi.org/10.1007/s11701-021-01198-4
This record's URL: https://www.repository.cam.ac.uk/handle/1810/334324
Rights
Licence:
http://creativecommons.org/licenses/by/4.0/
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.
Recommended or similar items
The current recommendation prototype on the Apollo Repository will be turned off on 03 February 2023. Although the pilot has been fruitful for both parties, the service provider IKVA is focusing on horizon scanning products and so the recommender service can no longer be supported. We recognise the importance of recommender services in supporting research discovery and are evaluating offerings from other service providers. If you would like to offer feedback on this decision please contact us on: support@repository.cam.ac.uk